About: Diagnosis and treatment of community‐acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnosis and treatment of community‐acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Diagnosis and treatment of community‐acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association
Creator	Zhang, Yan Shi, Yi Zhang, Jing Cao, Bin Chen, Yu Huang, Yi Shen, Ning Xu, Jin-Fu Fan, Hong Cheng, Jian Li, \| Wang, \| Tian, Qi, \| Xiang, \| Bei He, \| He, -Xian Jiang, \| Jie, \| Liu, You-Ning Qu, Ming She, Dan-Yang Xin-Lun, \|
source	PMC
abstract	Community‐acquired pneumonia (CAP) in adults is an infectious disease with high morbidity in China and the rest of the world. With the changing pattern in the etiological profile of CAP and advances in medical techniques in diagnosis and treatment over time, Chinese Thoracic Society of Chinese Medical Association updated its CAP guideline in 2016 to address the standard management of CAP in Chinese adults. Extensive and comprehensive literature search was made to collect the data and evidence for experts to review and evaluate the level of evidence. Corresponding recommendations are provided appropriately based on the level of evidence. This updated guideline covers comprehensive topics on CAP, including aetiology, antimicrobial resistance profile, diagnosis, empirical and targeted treatments, adjunctive and supportive therapies, as well as prophylaxis. The recommendations may help clinicians manage CAP patients more effectively and efficiently. CAP in pediatric patients and immunocompromised adults is beyond the scope of this guideline. This guideline is only applicable for the immunocompetent CAP patients aged 18 years and older. The recommendations on selection of antimicrobial agents and the dosing regimens are not mandatory. The clinicians are recommended to prescribe and adjust antimicrobial therapies primarily based on their local etiological profile and results of susceptibility testing, with reference to this guideline.
has issue date	2017-09-26(xsd:dateTime)
bibo:doi	10.1111/crj.12674
bibo:pmid	28756639
has license	no-cc
sha1sum (hex)	5bb5e03741d4e34f7595f59951d101b393657277
schema:url	https://doi.org/10.1111/crj.12674
resource representing a document's title	Diagnosis and treatment of community‐acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association
has PubMed Central identifier	PMC7162259
has PubMed identifier	28756639
schema:publication	Clin Respir J
resource representing a document's body	covid:5bb5e03741d4e34f7595f59951d101b393657277#body_text
is schema:about of	named entity 'Chinese Medical Association' named entity 'anticholinergic' named entity 'neutropenia' named entity 'cefdinir' named entity 'Gentamicin' named entity 'infection' named entity 'antimicrobial' named entity 'epidemiological' named entity 'b-lactamase' named entity 'assisted ventilation' named entity 'pneumonia' named entity 'Staphylococcus aureus' named entity 'nutrition' named entity 'mycoplasma' named entity 'treatment response' named entity 'quinolones' named entity 'treatment protocol' named entity 'necrosis' named entity 'moxifloxacin' named entity 'symptoms and signs' named entity 'risk of death' named entity 'hemoptysis' named entity 'pneumonia' named entity 'macrolides' named entity 'noninfectious' named entity 'cefoperazone' named entity 'health maintenance' named entity 'adenovirus' named entity 'cohort studies' named entity 'pharmacokinetic' named entity 'Cephalosporins' named entity 'China.' named entity 'community-acquired' named entity 'pathogens' named entity 'underlying diseases' named entity 'Escherichia coli' named entity 'acute respiratory failure' named entity 'dyspnea' named entity 'nutrition' named entity 'pneumococcal polysaccharide vaccine' named entity 'ciprofloxacin' named entity 'Legionella' named entity 'chest pain' named entity 'protein' named entity 'meta-analyses' named entity 'gram-negative bacteria' named entity 'chest pain' named entity 'Hydrocortisone succinate' named entity 'quinolones' named entity 'S. pneumoniae' named entity 'antibacterial drugs' named entity 'China' named entity 'clarithromycin' named entity 'pathogens' named entity 'CURB-65 score' named entity 'incubation period' named entity 'immunocompetent' named entity 'pathogens' named entity 'imipenem'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software